Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Patient-Specific Implantation Technique to Obtain Neo-Commissural Alignment With Self-Expanding Transcatheter Aortic Valves

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Technical Considerations for Transcatheter Aortic Valve Replacement With the Navitor Transcatheter Heart Valve

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVR: A Multicenter Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Redo-TAVR: What About the Coronary Arteries?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term prognosis following hospitalization for acute myocarditis - a matched nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Max Liebregts
  • Lothar Faber
  • Morten K Jensen
  • Pieter A Vriesendorp
  • Jaroslav Januska
  • Jan Krejci
  • Peter R Hansen
  • Hubert Seggewiss
  • Dieter Horstkotte
  • Radka Adlova
  • Henning Bundgaard
  • Jurriën M Ten Berg
  • Josef Veselka
Vis graf over relationer

OBJECTIVES: The aim of this study was to describe the safety and outcomes of alcohol septal ablation (ASA) in younger patients with obstructive hypertrophic cardiomyopathy.

BACKGROUND: The American College of Cardiology Foundation/American Heart Association guidelines reserve ASA for older patients and patients with serious comorbidities. Data on long-term age-specific outcomes after ASA are scarce.

METHODS: A total of 1,197 patients (mean age 58 ± 14 years) underwent ASA for obstructive hypertrophic cardiomyopathy. Patients were divided into young (≤50 years), middle-age (51 to 64 years), and older (≥65 years) groups.

RESULTS: Thirty-day mortality and pacemaker implantation rates were lower in young compared with older patients (0.3% vs. 2% [p = 0.03] and 8% vs. 16% [p < 0.001], respectively). Ninety-five percent of young patients were in New York Heart Association functional class I or II at last follow-up. During a mean follow-up period of 5.4 ± 4.2 years, 165 patients (14%) died. Annual mortality rates of young, middle-age, and older patients were 1%, 2%, and 5%, respectively (p < 0.01). Annual adverse arrhythmic event rates were similar in the 3 age groups at about 1% (p = 0.90). Independent predictors of mortality in young patients were age, female sex, and residual left ventricular outflow tract gradient. Additionally, young patients treated with ≥2.5 ml alcohol had a higher all-cause mortality rate (0.6% vs. 1.4% per year in patients treated with <2.5 ml, p = 0.03).

CONCLUSIONS: ASA in younger patients with obstructive hypertrophic cardiomyopathy was safe and effective for relief of symptoms at long-term follow-up. The authors propose that the indication for ASA can be broadened to younger patients.

OriginalsprogEngelsk
TidsskriftJACC: Cardiovascular Interventions
Vol/bind10
Udgave nummer11
Sider (fra-til)1134-1143
Antal sider10
ISSN1936-8798
DOI
StatusUdgivet - 12 jun. 2017

ID: 51686610